Clinical case: idelalisib-induced immunoglobulin flare

Immunopharmacology and Immunotoxicology
Jan NovakTomas Kozak

Abstract

IgM flare is a transient, treatment-induced, increase of monoclonal IgM levels in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) patients. Until recently this phenomenon was observed in patients treated with Cladribine and Rituximab. Here we report a case of a heavily pretreated chronic lymphocytic leukemia patient with an atypically high immunoglobulin production who developed clinically significant immunoglobulin flare following Idelalisib treatment.

References

May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosNikolaos Anagnostopoulos
May 16, 2003·The New England Journal of Medicine·Vandana M KrishnaKurt J Bloch
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S P TreonK C Anderson
Apr 22, 2005·American Journal of Clinical Pathology·Pei LinL Jeffrey Medeiros

❮ Previous
Next ❯

Citations

Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Giuseppe Curigliano, Rashmi R Shah

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.